Emmessar biotech & Nutrition Limited announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating improved profitability compared to the previous year. The company's Board of Directors approved these results at their meeting held on February 11, 2026.

Financial Performance Overview

The company reported strong financial performance for the third quarter of FY26, with significant improvement in net profitability year-over-year.

Nine-Month Performance

For the nine-month period ended December 31, 2025, Emmessar Biotech & Nutrition Limited maintained steady performance across key financial metrics.

Segment-wise Revenue Analysis

The company operates through multiple business segments, with rent on leasehold land being the primary revenue contributor.

Q3 FY26 Segment Performance:

• Healthcare: ₹9.34 lakhs revenue, ₹5.80 lakhs profit before tax
• Rent on leasehold land: ₹41.33 lakhs revenue, ₹41.10 lakhs profit before tax
• Others: ₹7.65 lakhs revenue, ₹7.65 lakhs profit before tax

Expense Management

Total expenses for Q3 FY26 were ₹45.47 lakhs compared to ₹39.94 lakhs in Q3 FY25. Key expense components included employee benefit expenses of ₹32.99 lakhs and other expenses of ₹6.38 lakhs. The company maintained disciplined cost management across operational categories.

Regulatory Compliance

The financial results have been prepared in accordance with Indian Accounting Standard 34 and comply with Regulation 33 of SEBI Listing Regulations. The results were reviewed by the Audit Committee and subjected to limited review by statutory auditors V. Nagarajan & Co. The company reported no investor complaints during the quarter ended December 31, 2025.

Emmessar Biotech Nutrition Limited has released its unaudited financial results for the second quarter of the fiscal year 2026, ending September 30, 2025. The company, which operates in the healthcare and real estate sectors, reported a decline in revenue and a shift to loss compared to the previous quarter.

Financial Highlights

Key Points

Revenue and Profitability

• The company's revenue from operations for Q2 FY2026 stood at ₹9.26 lakhs, marking a decrease from ₹13.90 lakhs reported in the previous quarter.
• Emmessar Biotech Nutrition recorded a net loss after tax of ₹3.67 lakhs for Q2 FY2026, contrasting with a net profit of ₹30.55 lakhs in the preceding quarter.
• For the first half of FY2026, the company reported a total revenue of ₹23.16 lakhs and a net profit after tax of ₹26.88 lakhs.

Business Operations

• The company operates in two segments: Healthcare and Rent on leasehold land.

Corporate Governance

• The financial results were reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on November 12, 2025.

Share Capital

• Emmessar Biotech Nutrition's paid-up equity share capital stands at ₹499.61 lakhs, with shares having a face value of ₹10 each.

The company's performance in Q2 FY2026 indicates a challenging period with reduced revenue and a shift to loss. However, the half-yearly results remain positive, suggesting potential volatility in the company's quarterly performance.